The therapeutic system has an active substance impermeable rear layer (1), a detention adhesive, and a matrix layer (2) containing an active substance buprenorphine and carboxylic acid i.e. levulinic acid, and a detachable protection layer (3). The matrix layer is formed on the basis of amine-resistant dimethyl polysiloxane or polyisobutylene, where the matrix layer dissolves the buprenorphine in the carboxylic acid. A solution in a form of droplets is dispersed in the matrix layer, which stays in diffusible contact with a polyacrylate layer.